Assessing the potential of gastroretentive technology for gastric cancer targeting

Swati Saini Jatin Chhabra Archana Sharma Manish Kumar Inderbir Singh Rakesh Pahwa   

Open Access   

Published:  Dec 20, 2022

DOI: 10.7324/JAPS.2023.130301
Abstract

Gastric cancer is a multifactorial disease and a major cause of mortality across the globe. Initially, gastric cancer reveals no related symptoms; therefore, patients come to the notice of clinicians only in advanced stages. Chemotherapy, radiation, surgery, immunotherapy, etc. are some of the common treatment interventions for stomach cancer. Traditional oral chemotherapy reveals several limitations, including inadequate oral bioavailability, repeated dosage, low solubility, short gastric residence period, etc. To address these issues, unique technological advancements recognized as gastroretentive drug delivery systems (GRDDS) have been explored by scientists globally. The GRDDS has acquired tremendous significance in the avenue of oral drug delivery. This is a frequently utilized and encouraging methodology of retaining the dosage form in the stomach for a prolonged time and slowly releasing the drug, which can address many of the problems associated with traditional oral delivery. The current review addresses the causes of gastric cancer, significant insights, and classification along with treatment strategies for gastric cancer. Advancements in gastroretentive technology in the treatment of stomach cancer are also focused in the present paper.


Keyword:     Gastric cancer Helicobacter pylori anticancer drugs therapeutic interventions gastroretentive technology floating dosage forms


Citation:

Saini S, Chhabra J, Sharma A, Kumar M, Singh I, Pahwa R. Assessing the potential of gastroretentive technology for gastric cancer targeting. J Appl Pharm Sci, 2022. https://doi.org/10.7324/JAPS.2023.130301

Copyright: © The Author(s). This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HTML Full Text

Reference

Adibkia K, Hamedeyazadan S, Javadzadeh Y. Drug release kinetics and physicochemical characteristics of floating drug delivery system. Expert Opin Drug Deliv, 2011; 8(7):891-903. https://doi.org/10.1517/17425247.2011.574124

Ahmed N. A 23 years of the discovery of Helicobacter pylori: is the debate over? Ann Clin Microbiol Antimicrob, 2005; 17:1-3. https://doi.org/10.1186/1476-0711-4-17

Ahn HS, Kim JW, Yoo MW, Park DJ, Lee HJ, Lee KU, Yang HK. Clinicopathological features and surgical outcomes of patients with remnant gastric cancer after a distal gastrectomy. Ann Surg Oncol, 2008; 15(6):1632-9. https://doi.org/10.1245/s10434-008-9871-8

Ali RY, Kamran BL, Peivand B, Maryam R Zahra K. Risk factors for gastric cancer: a systemic review. Asian Pac J Cancer Prev, 2018; 19(3):591-603.

Anothra P, Pradhan D, Naik PK, Ghosh G, Rath G. Development and characterization of 5-fluorouracil nanofibrous film for the treatment of stomach cancer. J Drug Deliv Sci Technol, 2020; 61:1-26. https://doi.org/10.1016/j.jddst.2020.102219

Arora S, Ali J, Ahuja A, Khar Roop K, Baboota S. Floating drug delivery systems: a review. AAPS Pharm Sci Tech, 2005; 6(3):372-90. https://doi.org/10.1208/pt060347

Arya P, Pathak K. Assessing the viability of microsponges as gastro retentive drug delivery system of curcumin optimization and pharmacokinetics. Int J Pharm, 2014; 460:1-2. https://doi.org/10.1016/j.ijpharm.2013.10.045

Asakura H, Hashimoto T, Harada H, Mizumoto M, Furutani K, Hasuike N, Matsuoka M, Ono H, Boku N, Nishimura T. Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? J Cancer Res Clin Oncol, 2011; 137(1):125-30. https://doi.org/10.1007/s00432-010-0866-z

Awasthi R, Kulkarni GT. Decades of research in drug targeting to the upper gastrointestinal tract using gastroretention technologies: where do we stand. Drug Deliv, 2014; 23(2):1-17. https://doi.org/10.3109/10717544.2014.936535

Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Control Release, 2006;111(1-2):1-18. https://doi.org/10.1016/j.jconrel.2005.10.031

Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci, 2012; 9(3):193-9. https://doi.org/10.7150/ijms.3635

Berlth F, Bollschweiler E, Drebber U, Hoelscher AH, Moenig S. Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value. World J Gastroenterol, 2014; 20(19):5679-84. https://doi.org/10.3748/wjg.v20.i19.5679

Bhardwaj P, Chaurasia D, Singh R, Swarup A. Development and characterization of novel site specific hollow floating microspheres bearing 5-Fu for stomach targeting. Sci World J, 2014:705259-70. https://doi.org/10.1155/2014/705259

Biagioni A, Skalamera I, Peril S, Schiavone N, Cianchi F, Giommoni E, Magnelli L, Papucci L. Update on gastric cancer treatments and gene therapies. Cancer Metastasis Rev, 2019:537-48. https://doi.org/10.1007/s10555-019-09803-7

Boland CR, Yurgelun MB. Historical perspective on familial gastric cancer. Cell Mol Gastroenterol and Hepatol, 2017; 3(2):192-200 https://doi.org/10.1016/j.jcmgh.2016.12.003

Chang CJ, Tu YK, Chen PC, Yang HY. Talc exposure and risk of stomach cancer: systematic review and meta-analysis of occupational cohort studies. J Formos Med Assoc, 2018; 119(4):781-92. https://doi.org/10.1016/j.jfma.2018.07.015

Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA, Psyrri A. Medical management of gastric cancer a 2017 update. Cancer Med, 2018; 7(1):123-33. https://doi.org/10.1002/cam4.1274

Chen R, Guo X, Liu X, Cui H, Wang R, Han J. Formulation and statistical optimization of gastric floating alginate/oil/chitosan capsules loading procyanidins: in vitro and in vivo evaluations. Int J Bio Macromol, 2018; 108:1082-91. https://doi.org/10.1016/j.ijbiomac.2017.11.032

Das S, Kaur S, Rai KV. Gastroprotective drug delivery system: a recent update on clinical pertinence and drug delivery. Drug Deliv Transl Res, 2020, 1-28.

Du F, Wu Y, Du F, Zhang L, Feng W, Zhao L. Construction of catechol-grafted chitosan alginate/barium sulfate microcapsules for computed tomography real-time imaging and gastroretentive drug delivery. Int J Nanomedicine, 2019; 14:6001-18. https://doi.org/10.2147/IJN.S204237

Ehsan TD, Mohamed IN, Ali K, Behnam K, Abdoreza SF, Hamid AJ. Preparation and characterization of a gastric floating dosage form of capecitabine. BioMed Res Int, 2013:1-8. https://doi.org/10.1155/2013/495319

El Nabarawi MA, Teaima MH, EL-Monem RAA, El Nabarawi NA, Gaber DA. Formulation release characteristics and bioavailability study of gastroretentive floating matrix tablet and floating raft system of meheverine HCl. Drug Des Dev Ther, 2017; 11:1080-93. https://doi.org/10.2147/DDDT.S131936

Fabian MJ, Michael B. Updates on management of gastric cancer. Curr Oncol Rep, 2019; 21(8):1-9. https://doi.org/10.1007/s11912-019-0820-4

Fontana MG, La Pinta M, Moneghini D, Villanacci V, Donato F, Rindi G, Paparini S, Baronvhelli C, Bertoli G, Alquati P. Prognostic value of Goseki histological classification in adenocarcinoma of the cardia. Br J Cancer, 2003; 88(3):401-5. https://doi.org/10.1038/sj.bjc.6600663

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 2014; 383(9911):31-9. https://doi.org/10.1016/S0140-6736(13)61719-5

Geetha T, Deol PK, Kaur IP. Role of sesamol-loaded floating beads in gastric cancers a pharmacokinetic and biochemical evidence. J Microencapsul, 2015; 32(5):478-87. https://doi.org/10.1039/C4RA10926K

Goindi S., Mann K., Aggarwal N. Gastro-retentive floating beads of curcumin β cyclodextrin complex to treat stomach tumors. Altern Med Stud, 2011; 1(1):49-53. https://doi.org/10.4081/ams.2011.e12

Goseki N, Takizawa T, Koike M. Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma. Gut, 1992; 33(5):606-12. https://doi.org/10.1136/gut.33.5.606

Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 2008; 19(9):1523-9. https://doi.org/10.1093/annonc/mdn169

He C, Tu H, Sun L, Xu Q, Li P, Gong Y, Dong N Yuan Y. Helicobacter pylori-related host gene polymorphisms associated with susceptibility of gastric carcinogenesis: a two-stage case control study in Chinese. Carcinogenesis, 2013; 34(7):1450-7. https://doi.org/10.1093/carcin/bgt079

Hejaji R, Amiji M. Stomach specific and anti H.pylori therapy: Preparation and characterization of tetracycline of a floating multiple unit capsule a high density loaded chitosan microcapsules. Int J Pharm, 2002; 235:87-94. https://doi.org/10.1016/S0378-5173(01)00985-1

Herrera V Parsonnet J. Helicobacter pylori and gastric adenocarcinoma. Clin Microbiol and Infect, 2009; 15(11):971-6. https://doi.org/10.1111/j.1469-0691.2009.03031.x

Ishak RAH. Buoyancy-generating agents for stomach-specific drug delivery: an overview with special emphasis on floating behavior. J Pharm Pharm Sci, 2015; 18(1):77-100. https://doi.org/10.18433/J3602K

Jasim IK, Alaa AA, Shaimaa N, Abd A. Nanosponge based gastroretentive drug delivery system of 5-fluorouracil for gastric cancer targeting. Int J Drug Deliv Technol, 2021; 11(3):959-63.

Jun X, Liling F, Li J. Immunotherapy of gastric cancer: past, future perspective and challenges. Pathol Res and Pract, 2021; 218:1-11. https://doi.org/10.1016/j.prp.2020.153322

Kang Y-K, Boku N, Satoh T, Ryu MH, Chao Y, Kato K. Nivolumab in patients with advanced gastric or gastro esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 2017; 390(10111):2461-71. https://doi.org/10.1016/S0140-6736(17)31827-5

Khan MA, Akhtar N, Sharma V, Pathak K. Product development studies on sonocrystallized curcumin for the treatment of gastric cancer. Pharmaceutics, 2015; 7(2):43-63. https://doi.org/10.3390/pharmaceutics7020043

Komatsu S, Ichikawa D, Okamoto K, Ikoma D, Tsujiura M, Nishimura Y, Murayama Y, Shiozaki A, Ikoma H, Kuriu Y, Nakanishi M, Fujiwara H, Ochiai T, Kokuba Y, Otsuji E. Progression of remnant gastric cancer is associated with duration of follow-up following distal gastrectomy. World J Gastroenterol, 2012; 18(22):2832-6. https://doi.org/10.3748/wjg.v18.i22.2832

Kotreka U, Moji CA. Gastroretentive floating drug-delivery systems: a critical review. Crit Rev Ther Drug Carr Syst, 2011; 28(1):47- 99. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v28.i1.20

Krishana, Kumar A, Shrivastav R. In vitro in vivo studies on floating microspheres for gastroretentive drug delivery system: a review. Asian J Pharm Clin Res, 2021; 14(1):13-26. https://doi.org/10.22159/ajpcr.2021.v14i1.39183

Kuipers EJ. Pernicious anemia, atrophic gastritis, and the risk of gastric cancer. Clin Gastroenterol Hepatol, 2015; 13(13):2290-2. https://doi.org/10.1016/j.cgh.2015.07.013

Kumar M, Kaushik D, An overview on various approaches and recent patents on gastroretentive drug delivery systems, Recent Pat Drug Deliv Formul, 2018; 12:84-92. https://doi.org/10.2174/1872211312666180308150218

Kumar R, Philip A. Gastroretentive dosage forms for prolonging gastric residence time. Int J Pharm Med, 2007; 21:157-71. https://doi.org/10.2165/00124363-200721020-00005

Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand, 1965; 64(1):31-49. https://doi.org/10.1111/apm.1965.64.1.31

Lee VHL, Mukherjee SK. Drug delivery: oral colon specific. In: Swarbrick J (ed.). Encyclopedia of pharmaceutical technology, Informa Healthcare, London, UK, pp 1228-41, 2002.

Lin XJ, Wang CP, Liu XD, Yan KK, Li S, Bao H., Zhao LY, Liu X. Body mass index and risk of gastric cancer: a meta-analysis. Jpn J Clin Oncol, 2014; 44(9):783-91. https://doi.org/10.1093/jjco/hyu082

Lopes CM, Bettencourt C, Rossi A, Buttini F, Barata P. Overview on gastroretentive drug delivery systems for improving drug bioavailability. Int J Pharm, 2016; 510(1):144-58. https://doi.org/10.1016/j.ijpharm.2016.05.016

Ma K, Baloch Z, He TT, Xia X. Alcohol consumption and gastric cancer risk: a meta-analysis. Med Sci Monit, 2017; 23:238-46. https://doi.org/10.12659/MSM.899423

Malik R, Garg T, Goyal AK, Rath G. Polymeric nanofibers: targeted gastro-retentive drug delivery systems. J Drug Target, 2015;23(2):109-24. https://doi.org/10.3109/1061186X.2014.965715

Mandal UK, Chatterjee B, Senjoti FG. Gastro-retentive drug delivery systems and their in vivo success: a recent update. Asian J Pharm Sci, 2016; 11(5):575-84. https://doi.org/10.1016/j.ajps.2016.04.007

Martin IG, Dixon MF, Sue-Ling H, Axon AT, Johnston D. Goseki histological grading of gastric cancer is an important predictor of outcome. Gut, 1994; 35(6):758-63. https://doi.org/10.1136/gut.35.6.758

Meghpara K, Vaghashiya J, Shah NH, Desai D, Phuapradit W, Sandhu HK, Vaka SRK, Shelke NB, Chatterji A, Gastroretentive dosage form for sustained drug delivery, US 2021/0236421 A1, 2021.

Mellman I, George C, Glenn D. Cancer immunotherapy comes of age. Nature, 2011:480-9. https://doi.org/10.1038/nature10673

Melocchi A, Uboldi M, Inverardi N, Briatico Vangosa F, Baldi F, Pandini S. Expandable drug delivery system for gastric retention based on shape memory polymers: development via 4D printing and extrusion. Int J Pharm, 2019; 570:1-36. https://doi.org/10.1016/j.ijpharm.2019.118700

Menachem AB, Zalit I, Expandable gastroretentive dosage form, US 2022/0160630 A1, 2022.

Mirani AG, Patankar SP, Kadam VJ. Risk based approach for systemic development of gastroretentive drug delivery system. Drug Deliv Trans Res, 2016; 6(5):579-96. https://doi.org/10.1007/s13346-016-0315-x

Mohapatra PR, Satyavani CH, Sahoo S. Design and development of carvedilol gastroretentive floating drug delivery systems using hydrophilic polymers and in vitro characterization. Int J Pharm Pharm Sci, 2020;12(7):66-73. https://doi.org/10.22159/ijpps.2020v12i7.38024

Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington MK, Carneiro F, Cree IA. The 2019 WHO classification of tumors of the digestive system. Histopathol, 2020;76(2):182-8. https://doi.org/10.1111/his.13975

Nana C, Jing'e N, Qian L, Jianyin L, Xinping C, Yuan R, Guotai W, Yingqian L, Yanbin S. Development and evaluation of a new gastroretentive drug delivery system: nanomicelles-loaded floating mucoadhesive beads. J Drug Deliv Sci Technol, 2019; 51:485-92. https://doi.org/10.1016/j.jddst.2019.03.024

Narayana CR, Basavaraj BV, Madhavan V. Microballoons of famotidine: a non-effervescent gastroretentive controlled drug delivery system using Eudragit L-100. Int J Pharm Sci Rev Res, 2010; 5(10):135-9.

Narvekar M, Xue HY, Eoh JY, Wong LH. Nanocarrier for poorly water-soluble anticancer drugs-barriers of translation and solutions. AAPS Pharm Sci Tech, 2014; 15(4):822-33. https://doi.org/10.1208/s12249-014-0107-x

Neumann M, Heimhardt C, Seidlitz K, Koziolek M, Schneider F, Schiller C, Weitschies W. Development of a furosemide-containing expandable system for gastric retention. J Control Release, 2021; 338: 105-18. https://doi.org/10.1016/j.jconrel.2021.08.026

Nygren P. What is cancer chemotherapy? Acta Oncologica, 2001; 40:166-74. https://doi.org/10.1080/02841860151116204

Olnes MJ, Martinson HA. Recent advances in immune therapies for gastric cancer. Cancer Gene Ther, 2021:924-34. https://doi.org/10.1038/s41417-021-00310-y

Pahwa R, Bhardwaj BY, Sharma A, Piplani M, Kumar M. Gastroretentive floating technology for eradication of Helicobactor pylori: an insight view. Int J Appl Pharm, 2021;13(3):1-10. https://doi.org/10.22159/ijap.2021v13i3.39369

Pahwa R, Bisht S, Kumar V, Kohli K. Recent advances in gastric floating drug delivery technology: a review. Curr Drug Deliv, 2013; 10(3):286-98. https://doi.org/10.2174/1567201811310030005

Pahwa R, Jindal S, Chhabra L, Dutt H Rao R. Development and in vitro characterization of effervescent floating drug delivery system of famotidine. Int J Pharm Sci Res, 2011; 3(1):241-6.

Pahwa R, Saini N, Kumar V, Kohli K. Chitosan-based gastroretentive floating drug delivery technology: an updated review. Expert Opin Drug Deliv, 2012a; 9(5):525-39. https://doi.org/10.1517/17425247.2012.673581

Pahwa R, Singh M, Kumar V, Kohli K. Recent advances and patent perspectives in gastroretentive technology. Recent Pat Drug Deliv and Formul, 2012b; 6(3):278-90. https://doi.org/10.2174/187221112802652660

Patil JM, hirlekar RS, Gide PS and Kadam VJ. Trends in floating drug delivery system. J Sci Ind Res, 2006; 65:11-21.

Pawar VK, Kansal S, Asthana S, Chourasia MK. Industrial perspective of gastroretentive drug delivery systems: physicochemical, biopharmaceutical, technological and regulatory consideration. Expert Opin Drug Deliv, 2012; 9(5):551-65. https://doi.org/10.1517/17425247.2012.677431

Pawar VK., Kansal S, Garg Garima, Awasthi R, Singodia D, Kulkarni GT. Gastroretentive dosage forms: a review with special emphasis on floating drug delivery systems. Drug Deliv, 2011; 18(2):97-110. https://doi.org/10.3109/10717544.2010.520354

Prajapati ST, Patel LD, Patel CN. Polymers for floating drug delivery system. Syst Rev Pharm, 2011; 2(1):1-7. https://doi.org/10.4103/0975-8453.83431

Prajapati VD, Jani GK, Khutliwala TA, Zala BS. Raft forming system-An upcoming approach of gastroretentive drug delivery system. J Control Release, 2013; (2):151-65. https://doi.org/10.1016/j.jconrel.2013.02.028

Rai VK, Mishra N, Yadav KS, Yadav NP. Nanoemulsion as pharmaceutical carrier for dermal and transdermal drug delivery: formulation development, stability issues, basic considerations and applications. J Control Release, 2018; 270:203-25. https://doi.org/10.1016/j.jconrel.2017.11.049

Raviteja G, Narayana RKVV, Baskaran M, Meghana G, Ganesh G. A mucoadhesive gastroretentive dosage form for valacyclovir. Int J Pharm Pharm Sci, 2014; 6(9):422-7.

Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Gastroenterol Rev, 2019; 14(1):26-38. https://doi.org/10.5114/pg.2018.80001

Robert S, Ma?gorzata S, Jerzy M, G Johan A Offerhaus, Ryszard M, Wojciech PP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res, 2018; 10:239-48. https://doi.org/10.2147/CMAR.S149619

Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm, 1996; 136(1-2):117-39. https://doi.org/10.1016/0378-5173(96)85200-8

Sadjadi A, Derakhshan MH, Yazdanbod A, Boreiri M, Parsaeian MBM, Alimohammadian M, Samadi F, Etemadi A, Pourfarzi F, Ahmadi E, Delavari A, Islami F, Farzadfar F, Sotoudeh M, Nikmanesh A, Alizadeh BZ, De BGH. Malekzadeh R. Neglected role of hookah and opium in gastric carcinogenesis: a cohort study on risk factors and attributable fractions. Int J Cancer, 2014; 134(1):181-8. https://doi.org/10.1002/ijc.28344

Sastre J, Jose AS, Eduardo DR. Chemotherapy for gastric cancer. World J Gastroenterol, 2006; 12(2):204-13. https://doi.org/10.3748/wjg.v12.i2.204

Sethuraman V, Hedden DB, Leskow KM, Gastro - retentive sustained - release oral dosage form of a bile acid sequestrant, US 2022/0110876 A1, 2022.

Shah H, Prajapati S, Patel C. Gastroretentive drug delivery systems: from conception to commercial success. J Crit Rev, 2017; 4(2): 10-21. https://doi.org/10.22159/jcr.2017v4i2.16717

Shah HN, Desai D, Phuapradit W, Vaghashiya J, Meghpara K, Self regulating osmotic gastroretentive drug delivery system, US 2022/0031604 A1, 2022.

Shahiwala A. Formulation approaches in enhancement of patient compliance to oral drug therapy. Expert Opin Drug Deliv, 2011; 8(11):1521-9. https://doi.org/10.1517/17425247.2011.628311

Shishu, Gupta N, Aggarwal N. Bioavailability enhancement and targeting of stomach tumors using gastro-retentive floating drug delivery system of curcumin technical note. AAPS PharmSciTech, 2008; 9(3):810-3. https://doi.org/10.1208/s12249-008-9096-y

Shishu, Gupta N, Aggarwal N. Stomach-specific drug delivery of 5-fluorouracil using floating alginate beads. AAPS PharmSciTech, 2007; 8(2):143-9. https://doi.org/10.1208/pt0802048

Simons FJ, Wagner KG. Modeling, design and manufacture of innovative floating gastroretentive drug delivery systems based on hot-melt extruded tubes. Eur J Pharm Biopharm, 2019; 137:196-208. https://doi.org/10.1016/j.ejpb.2019.02.022

Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release, 2000; 63(3):235-59. https://doi.org/10.1016/S0168-3659(99)00204-7

Tey J, Back MF, Shakespeare TP, Mukherjee RK, Lu JJ, Lee KM, Wong LC, Leong CN, Zhu M. The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys, 2007; 67(2):385-88. https://doi.org/10.1016/j.ijrobp.2006.08.070

Tripathi J, Thapa P, Maharjan R, Jeong SH. Current state and future perspectives on gastroretentive drug delivery systems. Pharmaceutics, 2019; 11(4):1-22. https://doi.org/10.3390/pharmaceutics11040193

Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer, 2007; 10:75-83. https://doi.org/10.1007/s10120-007-0420-0

Vaghani S, Vasanti S, Chaturvedi K, Satish CS, Jivani NP. Stomach-specific drug delivery of 5-fluorouracil using ethyl cellulose floating microspheres. Pharm Dev Technol, 2010;15(2):154-61. https://doi.org/10.3109/10837450903085392

Vasvari G, Haimhoffer A, Horvath L, Budai I, Trencsenyi G, Beresova M. Development and characterization of gastroretentive solid dosage form based on melt foaming. AAPS PharmSciTech, 2019; 20:1-11. https://doi.org/10.1208/s12249-019-1500-2

Verma A, Dubey J, Hegde RR, Rastogi V, Pandit JK. Helicobacter pylori: past, current and future treatment strategies with gastroretentive drug delivery systems. J Drug Target, 2016; 24(10):897-915. https://doi.org/10.3109/1061186X.2016.1171326

Wu AH, Tseng CC, Bernstein L. Hiatal hernia. Reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer, 2003; 98(5):940-8. https://doi.org/10.1002/cncr.11568

Xiao YZ, Pei YZ and Mouard AM, Aboul S. From inflammation to gastric cancer: role of Helicobacter pylori. Oncol Lett, 2017; 13(2): 543-8. https://doi.org/10.3892/ol.2016.5506

Ye W, Chow WH, Lagergren J. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology, 2001; 121(6): 1286-93. https://doi.org/10.1053/gast.2001.29569

Zalit I, Menachem AB, Gastroretentive devices, US 2022/0008334 A1, 2022.

Zhang Y, Zhang L, Zhang Q, Zhang X, Zhang T, Wang B. Enhanced gastric therapeutic effects of Brucea javanica oil and its gastroretentive drug delivery system compared to commercial products in pharmacokinetics study. Drug Des Deliv Ther, 2018; 12:53544. https://doi.org/10.2147/DDDT.S155244

Zhao S, Lv Y, Zhang J Bin, Wang B, Lv GJ, Ma XJ. Gastroretentive drug delivery systems for the treatment of Helicobacter pylori. World J Gastroenterol, 2014; 20(8):9321-9.

Article Metrics

1 Absract views 9 PDF Downloads 10 Total views

   Abstract      Pdf Download

Related Search

By author names

Citiaion Alert By Google Scholar

Name Required
Email Required Invalid Email Address

Comment required